背景:抗B细胞成熟抗原(BCMA)嵌合抗原受体(CAR)T细胞LCAR-B38M(又称ciltacabtagene autoleucel)已在许多国家被批准用于治疗复发和难治性多发性骨髓瘤。LCAR-B38M的首次人体试验LEGEND-2产生了深度而持久的治疗反应。本文报道了LEGEN...
Subsequently, the CARTITUDE-1 study, a phase 1b/2 evaluation of LCAR-B38M CAR-T cells (known as ciltacabtagene autoleucel [cilta-cel] in this study), adopted the strategy of fludarabine + cyclophosphamide-based lymphodepletion and a single infusion of CAR-T cells in heavily pretreated...
6月1日,国内药企公布了BCMA导向CAR-T细胞疗法JNJ-4528(cilta-cel,LCAR-B38M CAR-T细胞自体回输制剂)的最新研究数据。结果表明,在先前接受过多种疗法(过度预治疗)的复发/难治性多发性骨髓瘤(RRMM)患者中,cilta-cel显示出持续的疗效和持续缓解! JNJ-4528是一种研究性B细胞成熟抗原(BCMA)导向的CAR-T疗法,用于...
Cilta-cel 西达基奥仑赛,LCARB38M CAR-T细胞制剂 @金斯瑞 发布了头条文章:《金斯瑞科普|Cilta-cel的惊人疗效!》 °金斯瑞科普|Cilta-cel的惊人疗效! 金斯瑞 金斯瑞科普|Cilta-cel的惊人疗效! 2 1 ñ4 2020-12-7 17:30 来自微博weibo.com ...
除了亘喜生物的GC012F外,传奇生物的靶向BCMA(B细胞成熟抗原)CAR-T疗法西达基奥仑赛(LCAR-B38M/JNJ-4528,下称cilta-cel)也一直备受关注,已经在治疗多发性骨髓瘤的临床试验中表现出卓越的抗癌活性。 此前cilta-cel曾在5月26日被美国FDA授予优先审评资格,然而西达基奥仑赛的审批却遭遇延迟,由2021年11月29日调整...
The autologous anti–B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell therapy LCAR-B38M has been approved for the treatment of relapsed and refractory multiple myeloma in many countries across the world under the name ciltacabtagene autoleucel. LEGEND-2 was the first-...
LEGEND-2 was a first-in-human phase 1 study of LCAR-B38M conducted in China, which showed encouraging efficacy and manageable safety in 74 patients (pts) with RRMM. The US phase 1b/2 CARTITUDE-1 and Chinese phase 2 CARTIFAN-1 trials of ciltacabtagene autoleucel, which expresses the ...